Monitor for FDA meeting outcome in mid-April and subsequent trial design announcement, which could serve as a near-term catalyst. The decision to focus on SCAC with a potentially small, fast registrational trial significantly de-risks the path to approval in a rare cancer with high unmet need.
ONCY drugs
ONCY drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 24 $1.13entry
- T+1 · 9mo ago −1.77%α −2.60% · $1.11
- T+5 · 9mo ago −7.96%α −6.93% · $1.04
- T+20 · 8mo ago −18.58%α −13.60% · $0.9200
- T+60 · 6mo ago −30.97%α −37.72% · $0.7800
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oncolytics Biotech announced it will prioritize registrational studies in squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC) based on promising data from Cohort 4 of its GOBLET study. The company has concluded enrollment in the GOBLET trial and plans to meet with the FDA in mid-April to finalize the design of a single-arm SCAC registrational study it believes can be completed with fewer than 100 patients. Enrollment in the pancreatic cancer (PDAC) arm has been stopped at ~20 patients per arm to conserve capital.
Key Facts
- Company will focus on registrational/enabling studies in SCAC and CRC based on GOBLET Cohort 4 data
- GOBLET study enrollment concluded; no further patients will be enrolled in PDAC cohorts
- Plans to meet FDA in mid-April to align on single-arm SCAC registrational study design
- Believes trial of fewer than 100 patients may be sufficient for FDA approval in SCAC
- Has sufficient cash to execute near-term milestones without immediate material dilution
- Will continue to follow existing PDAC cohort patients and report mature data
Financial Impact
Avoids immediate material dilution; capital allocation shifted to higher-potential indications
Risk Factors
- FDA may require larger or different trial design than anticipated
- Efficacy signal in SCAC may not hold in larger study
- Terminating PDAC enrollment may limit future opportunities in pancreatic cancer
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000006 |
| Document: oncygobletupdate.htm | 0001129928-26-000006 |
| Document: 0001129928-26-000006-index-headers.html | 0001129928-26-000006 |
| Document: 0001129928-26-000006-index.html | 0001129928-26-000006 |
| Document: 0001129928-26-000006.txt | 0001129928-26-000006 |
Track record
32 reports on ONCY
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 11 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers